Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 20, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management's discussion of financial results and a corporate update. Interested investors must register in advance or at least 15 minutes before the call. Access to the live webcast and replay will be available through the Events & Presentations page in TELA's investor section website.

TELA Bio (NASDAQ: TELA) has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units covering 7,200 shares of common stock, awarded to thirteen newly-hired employees on February 19, 2025. These grants, made under Nasdaq Rule 5635(c)(4), serve as employment compensation and incentives for new hires. The restricted stock units will vest equally over four years, contingent on continued employment with TELA Bio through the specified vesting dates.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to seven new employees. The grants, totaling 4,000 shares of common stock, were issued on January 21, 2025, under Nasdaq Rule 5635(c)(4). These RSUs will vest in equal annual installments over four years, contingent upon continued employment with the company. The grants were made as part of the employees' compensation packages and served as inducements for their acceptance of employment with TELA Bio, a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to three new employees. The grants, totaling 1,700 shares of common stock, were issued on December 11, 2024. These RSUs will vest in equal annual installments over four years, contingent on continued employment. The grants were made under Nasdaq Rule 5635(c)(4) as part of the employees' compensation packages and to incentivize their acceptance of employment with the company.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference. The company's management team will deliver a presentation on December 3rd, 2024, at 12:00 pm ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.

TELA Bio reported Q3 2024 revenue of $19.0 million, marking a 26% growth year-over-year. The company saw increased demand for OviTex® and OviTex PRS products, with unit sales volume growing 39% and 44% respectively. TELA completed a public offering raising $46.0 million gross proceeds and implemented efficiency measures expected to reduce 2025 operating expenses by $5.0-$10.0 million. The company reiterated its 2024 revenue guidance of $74.5-$76.5 million, representing 27-31% growth, though noting potential impact from IV fluid shortages. Q3 gross profit was $12.9 million (68% margin), with operating expenses at $22.2 million and a net loss of $10.4 million.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units covering 5,400 shares to six newly-hired employees. The grants, dated November 1, 2024, were made under Nasdaq Rule 5635(c)(4) as part of employment compensation packages. These restricted stock units will vest equally over four years, contingent on continued employment with the company.

TELA Bio has completed its previously announced public offering, raising $46 million in gross proceeds. The offering included 14,670,000 shares of common stock at $2.25 per share and 5,800,000 pre-funded warrants at $2.2499 each. The underwriters fully exercised their option to purchase additional shares. Canaccord Genuity and Lake Street Capital Markets served as joint bookrunners. The company plans to use the proceeds for general corporate purposes, including sales and marketing, R&D activities, administrative matters, working capital, and capital expenditures.

TELA Bio has announced the pricing of a public offering comprising 12,000,000 shares of common stock at $2.25 per share and pre-funded warrants for 5,800,000 shares at $2.2499 per warrant. The offering is expected to generate $40 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 2,670,000 additional shares. The offering, expected to close around October 24, 2024, will fund general corporate purposes, including sales, marketing, R&D, and working capital.